Fatty Acid Biosynthesis Disorders
GlobalData’s reports offer expert analysis, insights and opinions to companies in the world’s largest industries. Explore unique market-leading data today and benefit from access to actionable insight within the Fatty Acid Biosynthesis Disorders market. Reports cover market growth forecasts, trends and research, and more.
Browse our full list of Fatty Acid Biosynthesis Disorders market reports here.
- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Product Insights
Product Insights Sandhoff Disease (Jatzkewitz-Pilz Syndrome) – Drugs In Development, 2023 Sandhoff Disease (Jatzkewitz-Pilz Syndrome) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Drugs In Development, 2023’, provides an overview of the Sandhoff Disease (Jatzkewitz-Pilz Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Drugs In Development, 2023 Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Drugs In Development, 2023’, provides an overview of the Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Adrenomyeloneuropathy (AMN) – Drugs In Development, 2023 Adrenomyeloneuropathy (AMN) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Adrenomyeloneuropathy (AMN) - Drugs In Development, 2023’, provides an overview of the Adrenomyeloneuropathy (AMN) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adrenomyeloneuropathy (AMN), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Product Insights Fatty Acid Biosynthesis Disorders – Drugs In Development, 2023 Fatty Acid Biosynthesis Disorders – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Fatty Acid Biosynthesis Disorders - Drugs In Development, 2023’, provides an overview of the Fatty Acid Biosynthesis Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fatty Acid Biosynthesis Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Adrenoleukodystrophy) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update Adrenoleukodystrophy) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
$2,500 | June 2023 Adrenoleukodystrophy Clinical Trials Analysis Overview The Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) clinical trial market research report provides an overview of the Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Clinical trials scenario. This report provides top-line data relating to the clinical trials on Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.